Anti-IL-6 A breakthrough active immunotherapy for the treatment of osteoarthritis
- Coordinator
- Peptinov, France
- Runs
- 1 March 2024 to 28 February 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.0m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101145362
What the project is doing
In the project's own words, from its summary on CORDIS.
Osteoarthritis is a debilitating disease affecting the joint and a leading cause of disability worldwide. It affects at least 250m people and incurs healthcare costs of toward 0.5% of the GDP. Peptinov is developing an active immunotherapy that can halt inflammation-driven destruction of the cartilage in the joints. We use a unique approach to neutralise a key pro-inflammatory protein (IL-6) driving chronic inflammation.
Our vaccine-like approach stimulates the patients own immune system to produce antibodies against excess IL-6 and neutralise its biological function. By doing so we will halt disease progression. Our treatment will cost 5-10% of conventional immunotherapies as we inject patients with inexpensive, immunogenic peptides to stimulate production of endogenous antibodies. Phase I clinical trial yielded very encouraging preliminary safety and tolerability data on 24 patients.
This project will implement the Phase II clinical trial and make our therapy out-licensing ready.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Peptinov | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI